South Korea-based regenerative medicine company PharmaResearch announced on Thursday the signing of a strategic partnership agreement with VIVACY, a France-based global medical aesthetics company, to distribute its medical device brand Rejuran in the European market.
VIVACY is involved in the European medical aesthetics industry, with subsidiaries and branch offices across key cities in Europe to support its commercial and marketing network.
Through this strategic partnership, PharmaResearch aims to combine VIVACY's distribution network and its own expertise in the market to accelerate its brand's entry and presence in Europe.
The agreement is valued at approximately EUR54.5m over five years, and spans 22 countries, including the major Western European markets (United Kingdom, Germany, France, Italy, and Spain).
PharmaResearch plans to start distributing in the key European countries before the end of the year, followed by a phased rollout across the region.
Getinge launches Fluobeam LS for fluorescence‑guided small‑incision surgery
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Medtronic seeks expanded US approvals for Hugo robotic surgery system
Waters secures FDA clearance for BD BACTEC FXI Blood Culture System
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
ILC Dover adds Water for Injection (WFI) and custom chemical solutions to offerings
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Implantica submits final FDA response for RefluxStop PMA application
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System